Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
about
Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate CancerOverdiagnosis and overtreatment of prostate cancerManagement of low (favourable)-risk prostate cancerOutcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort.Trends in the treatment of localized prostate cancer using supplemented cancer registry data.Counseling patients about sexual health when considering post-prostatectomy radiation treatment.Time trends and local variation in primary treatment of localized prostate cancerThe relation of serum parathyroid hormone and serum calcium to serum levels of prostate-specific antigen: a population-based study.Primary radiotherapy vs conservative management for localized prostate cancer--a population-based study.Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up studyComparative effectiveness of external-beam radiation approaches for prostate cancer.Contemporary trends in low risk prostate cancer: risk assessment and treatmentPatient perspective on watchful waiting/active surveillance for localized prostate cancer.A multi-institutional evaluation of active surveillance for low risk prostate cancer.Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancerOutcomes of active surveillance for men with intermediate-risk prostate cancer.Can urinary PCA3 supplement PSA in the early detection of prostate cancer?Quantifying the role of PSA screening in the US prostate cancer mortality decline.Self-rated health as a tool for estimating health-adjusted life expectancy among patients newly diagnosed with localized prostate cancer: a preliminary study.The Thoc1 ribonucleoprotein and prostate cancer progression.Prostate cancer severity among low income, uninsured men.Clinical value of core length in contemporary multicore prostate biopsyThe median non-prostate cancer survival is more than 10 years for men up to age 80 years who are selected and receive curative radiation treatment for prostate cancer.Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse.Temporal trends in cause of death among Swedish and US men with prostate cancer.Role of active surveillance in the management of localized prostate cancer.An economic analysis of conservative management versus active treatment for men with localized prostate cancerThe Quantitative Criteria Based on the Fractal Dimensions, Entropy, and Lacunarity for the Spatial Distribution of Cancer Cell Nuclei Enable Identification of Low or High Aggressive Prostate Carcinomas.A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer.Safety of purified isoflavones in men with clinically localized prostate cancerRisk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml.Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI.Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer.A new approach to understanding racial disparities in prostate cancer treatment.Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics.Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group
P2860
Q26784517-608300FF-9941-47E8-8EE0-F62E9E5B8E3EQ26859596-7A575029-8EBE-4943-ABAA-4906B17A7FC9Q26996501-7BBFAC21-F5D8-4109-B320-6AC57E9E7EC8Q27308897-07B7047A-8B9F-49B0-BAD9-8FA22AA231F7Q30393322-ECCAE91A-136C-4716-9A4A-B738DFE442D6Q33561172-8C1EE3B5-C436-491B-8524-AF7764AF247CQ33671198-6AE90BA6-E59B-4904-8C3C-269078EAEE16Q33710312-CBEBF6FA-BE42-4ED4-B167-1BC0AF9C7999Q33710948-23971ED0-9FA6-4CE5-BDF3-906FFF10BEA6Q33810503-384E3A4A-D9CF-400A-ADDB-BCC292540889Q33919551-760DCF58-8149-438F-A8E3-09162D07958FQ33965083-AB195CF6-008E-431C-B896-BEDE93C57358Q34026731-52DCD944-C41B-4BBD-B944-9353ECFF69A6Q34330041-9470ED04-FEDA-4420-903C-6A2B556119EAQ34419421-AD8DD0C8-3D16-468F-A70B-DF3A4BB7A2DEQ34541484-DB6662C8-31D9-47CA-92D1-11A4F8231364Q34550547-F097803A-A1D5-47E9-9A47-4515069E2662Q34679207-B3DB1F0A-9EFA-4188-905F-AA7911214A75Q34692263-3AADA299-6BE3-437C-9C8E-5EDA9EA07974Q34720042-08D9901C-A99C-41B9-A0D8-4D8D92599A8BQ34733322-3304A8C6-C72A-4923-B421-582A8D3BEB61Q34736122-76B88F0B-4E62-43DC-88D3-522DB7168D12Q34909140-6242A965-AF2C-4FF1-8BE8-F523668AC94AQ35416415-440A6630-E29F-421A-8B8C-CD0FD6290AFEQ35834320-6B6D46FB-6640-41D3-B76F-4BAD367FD369Q35917103-5F2EE96F-461C-4DBC-B179-FD3139789D46Q36406313-C0916DB6-D583-41EA-B919-28F5F2F01B93Q36486777-79301BB1-1A7D-45A6-8916-EFB42F2E4390Q36520452-CB6DD9BF-131E-4002-8B43-187E3FA77101Q36520468-0F54FDA2-7FF6-49FE-A148-041E872CDB4BQ36568781-5D549F64-808D-44E4-BDCE-850F03DCD330Q36732271-6CB00196-B2FE-45F0-837C-5759AFDD38F3Q36741928-85DA9FF1-CA6B-477F-8A6A-E0433F6C9F32Q36837061-B5D9011D-7046-4C31-8DD1-1462A79CC4BBQ36837246-2A1BE639-2965-455C-B655-D86EEF341FB4Q36907574-C54E4F39-94F5-44E2-8335-0A6065778AEFQ36935758-BFF386ED-53BC-4D56-ABC9-EB3EA0407C9FQ36971869-74AD22A3-03F0-409E-B871-99D163CBF57DQ37037804-E454D4A1-D8EE-4808-A179-21F9C17ACF8AQ37107552-492B9C1C-79D4-4E5B-ABCB-1B3CB7188758
P2860
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Incidence of initial local the ...... e cancer in the United States.
@en
Incidence of initial local the ...... e cancer in the United States.
@nl
type
label
Incidence of initial local the ...... e cancer in the United States.
@en
Incidence of initial local the ...... e cancer in the United States.
@nl
prefLabel
Incidence of initial local the ...... e cancer in the United States.
@en
Incidence of initial local the ...... e cancer in the United States.
@nl
P2093
P2860
P356
P1476
Incidence of initial local the ...... e cancer in the United States.
@en
P2093
Brent K Hollenbeck
David C Miller
James E Montie
John T Wei
Stephen B Gruber
P2860
P304
P356
10.1093/JNCI/DJJ308
P407
P577
2006-08-01T00:00:00Z